Home>>Sci-Edu
Last updated at: (Beijing Time) Monday, June 09, 2003

Chinese Bio-tech Company Works on SARS Vaccines

The China National Biological Products Corporation (CNBPC), the largest bio-tech company in China, plans to spend 500 million yuan (60.46 million US dollars) developing vaccines against severe acute respiratory syndrome (SARS).


PRINT DISCUSSION CHINESE SEND TO FRIEND


The China National Biological Products Corporation (CNBPC), the largest bio-tech company in China, plans to spend 500 million yuan (60.46 million US dollars) developing vaccines against severe acute respiratory syndrome (SARS).

The first 50 million yuan has been invested in the early stage of the project, Wang Guoli, general manager with the CNBPC, said Monday.

The money will be spent in improving and rebuilding lab and production facilities for SARS vaccines, flu vaccines, blood products and other biological products, Wang said.

The company is carrying out three SARS-related research projects and has invested another 10 million yuan in developing SARS detecting methods, blood serums against SARS and relevant vaccines.

The CNBPC, founded in 1989 as the country's leading vaccine manufacturer, produces more than 50 kinds of vaccines.

The company is made up of six national research institutes on biological products in Chinese cities of Beijing, Changchun, Chengdu and Lanzhou.


Questions?Comments? Click here
    Advanced






Further Developments Made in SARS Vaccine Test

Chinese Scientists Make New Breakthrough in SARS Vaccine Research



>> Full Coverage

 


Efforts Urged to Frame China's Long-time Plan on Science,Technology ( 7 Messages)

Global Warming Troubles Qinghai-Tibet Railway Construction ( 7 Messages)

US Planning Historic Shift of Military Power Abroad: Report ( 26 Messages)

'Haven't got lost!': China's 1st SARS Patient out of Shadow ( 3 Messages)

Hu, Bush Pledge to Further Develop Constructive Ties of Cooperation ( 6 Messages)

G8 Meeting Urged to Highlight Water Issue in Africa ( 9 Messages)



Copyright by People's Daily Online, all rights reserved